3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
OTHER
4
INDUSTRY
2
NETWORK
1
FED
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
6
Myeloid
2
Dermatologic
2
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Interventions
pembrolizumab
181
Nivolumab
117
Ipilimumab
97
Dacarbazine
48
trametinib
37
dabrafenib
35
3-ingenyl angelate
35
Vemurafenib
33
cemiplimab
27
atezolizumab
24
Temozolomide
24
binimetinib
23
Paclitaxel
22
Imiquimod
22
encorafenib
17
avelumab
17
Carboplatin
17
Aminolevulinic Acid
17
spartalizumab
16
cobimetinib
16
Cyclophosphamide
15
Cisplatin
15
Fluorouracil
14
talimogene laherparepvec
13
HhAntag691
11
Gels
11
Drug Therapy
11
Bevacizumab
11
lenvatinib
10
durvalumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Tretinoin
×
Dermatologic
×
Clear all
NCT04303169
2025-10-27
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
146 enrolled
NCT04305041
2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
100 enrolled